Saturday, May 24, 2025

DEA Declares Cocaine Derivative Legal But Disagrees That Marijuana Should Be The Same

The Drug Enforcement Administration (DEA) is working on legalizing a cocaine derivative [18 F]FP-CIT, which is said to be a “diagnostic substance that is used in assisting the evaluation of adult patients with suspected Parkinsonian syndromes.”

“Based on consideration of all comments, the scientific and medical evaluation and accompanying recommendation of [the Department of Health and Human Services], and based on DEA’s consideration of its own eight-factor analysis, the Administrator finds that these facts and all relevant data demonstrate that [18 F]FP-CIT does not meet the requirements for inclusion in any schedule. As such, DEA is removing [18 F]FP-CIT form control under the [Controlled Substance Act (CSA)],” the agency declared.

But, even as the agency participates in a review of marijuana’s scheduling status ordered by the president, it is disregarding public submissions urging that cannabis, like the cocaine-derived substance it is now rescheduling, should be removed from federal authority.

Last year, the DEA suggested descheduling the chemical [18 F]FP-CIT and established a public comment period for people to weigh in. Advocates jumped on the bandwagon, requesting comparable treatment for marijuana due to the plant’s demonstrated medical usefulness.

The agency noted one commenter on the notice of proposed rulemaking who said they are opposed to decontrol the cocaine derivative, adding that “rescheduling cocaine, or any cocaine derivative, is a safety concern and such rescheduling would wrongly signal that cocaine is less harmful than cannabis.”

“DEA does not agree with the commenter’s concern about harm. [18 F]FP-CIT is derived from cocaine, a schedule II substance, via ecgonine, a schedule II substance,” the agency said.

The schedule II substance argument is the same on which the DEA is basing the rescheduling of the cocaine derivative, explaining that the chemical is similar to [123 I]ioflupane, known as DaTscan or [123 I]FP-CIT–a fellow schedule II substance which the DEA removed from CSA in September 2015.

A top Food and Drug Administration (FDA) official indicated late last month that the agency is looking into “what flexibilities we might have” in the federal government’s marijuana scheduling study, which Biden has mandated as a “very high priority.” The official also said that while FDA leads the scientific review, the DEA “has the final word” on any potential scheduling decision.

Marijuana–currently a Schedule I substance–is also difficult to be a subject of scientific research because of the restrictive status, the FDA official also noted.

Rahul Gupta, head of the White House Office of National Drug Control Policy, stated last month that Biden’s decision to issue a bulk cannabis pardon and direct the administrative review was “historic.” He also stated that there is “clearly” proof that marijuana has medical benefits.

Meanwhile, the DEA intends to more than double the amount of marijuana that may be lawfully synthesized for research in 2023, as well as dramatically raise the quota for psychedelics like psilocyn, LSD, and mescaline manufacturing. The agency further claimed that the increase in quota is proof that it supports rigorous study into the substances, but it has come under fire from advocates and scientists for policies that are seen as antagonistic to supporting studies.

A White House spokesperson confirmed to Marijuana Moment that Biden wants to approve a bipartisan marijuana research bill passed by Congress last week. The measure would give the US Attorney General 60 days to either approve or request additional information from a marijuana research applicant. It would also provide a more efficient route for researchers requesting larger quantities of cannabis.


Information for this briefing was found via Marijuana Moment and the sources mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

One Response

Leave a Reply

Video Articles

Toronto’s 2027 Condo Time Bomb: Financial Ruin for Pre-Construction Buyers | Mark Morris

Gold Industry Set For A $160 Billion Cash Haul In 2026!? | Terry Lynch – Power Metallic

$3200 Gold & The Miners Still Lagging!? | Cliff Hale-Sanders – Cerrado Gold

Recommended

Riverside Resources Spins Out Blue Jay Gold Corp

Canadian Copper Outlines $171 Million NPV, 36% IRR In PEA For Murray Brook And Caribou Complex

Related News

Doug Ford Doesn’t Want Cannabis-Smoking Lounges In Ontario: “Do It Somewhere Else”

Ontario Premier Doug Ford is thumbing down the proposal from the Ontario Chamber of Commerce...

Wednesday, March 22, 2023, 11:31:00 AM

OSC Withdraws Charges Against CannTrust Officials Following Inaccurate Witness Testimony

The Ontario Securities Commission withdrew its case against three CannTrust officials initially charged with securities...

Wednesday, December 14, 2022, 01:41:36 PM

Hold The Coke: BC Premier David Eby To Investigate Adastra’s Cocaine License

It seems British Columbia Premier David Eby was one of the last people to know...

Friday, March 3, 2023, 08:06:00 AM

Cocaine BC: Cannabis Firm Gets License To Process And Sell Cocaine

British Columbia cannabis firm Adastra Holdings (CSE: XTRX) recently announced that Health Canada approved Adastra...

Wednesday, March 1, 2023, 07:45:25 PM

DEA Asserts Final Authority in Marijuana Scheduling Review

The Drug Enforcement Administration (DEA) has emphasized its “final authority” in determining the scheduling of...

Thursday, January 4, 2024, 02:12:00 PM